STOCK TITAN

KORU Medical Systems (KRMD) COO buys 5,000 shares in open-market trade

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

KORU Medical Systems, Inc. Chief Operating Officer Christopher Pazdan bought 5,000 shares of Common Stock in an open-market purchase at $3.88 per share. Following this transaction, he directly owns 305,131 shares.

Positive

  • None.

Negative

  • None.
Insider Pazdan Christopher
Role Chief Operating Officer
Bought 5,000 shs ($19K)
Type Security Shares Price Value
Purchase Common Stock 5,000 $3.88 $19K
Holdings After Transaction: Common Stock — 305,131 shares (Direct, null)
Footnotes (1)
Shares purchased 5,000 shares Open-market purchase of Common Stock
Purchase price $3.88 per share Price paid in the May 14, 2026 transaction
Shares owned after transaction 305,131 shares Direct ownership following the reported purchase
open-market purchase financial
"transaction_action: "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Common Stock financial
"security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pazdan Christopher

(Last)(First)(Middle)
C/O KORU MEDICAL SYSTEMS, INC.
100 CORPORATE DRIVE

(Street)
MAHWAH NEW JERSEY 07430

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/14/2026P5,000A$3.88305,131D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
Remarks:
The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.
/s/ Thomas Adams - Attorney-in-Fact05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did KRMD executive Christopher Pazdan report?

Christopher Pazdan reported buying 5,000 shares of KORU Medical Systems Common Stock in an open-market purchase at $3.88 per share. After this transaction, he directly holds 305,131 shares, according to the Form 4 insider filing data.

What price did KRMD’s COO pay for the recently purchased shares?

KRMD’s Chief Operating Officer paid $3.88 per share for 5,000 Common Stock shares in an open-market purchase. This transaction was reported on Form 4 and increased his direct ownership to 305,131 shares after the trade.

How many KRMD shares does Christopher Pazdan own after the Form 4 transaction?

After the reported open-market purchase, Christopher Pazdan directly owns 305,131 shares of KORU Medical Systems Common Stock. This reflects the addition of 5,000 shares bought at $3.88 per share, as disclosed in the Form 4 insider filing.

Was the KRMD insider transaction an open-market purchase or another type?

The KRMD insider transaction was an open-market purchase of Common Stock. Christopher Pazdan bought 5,000 shares at $3.88 per share, and the Form 4 characterizes the transaction as a purchase in the open market or a private transaction.

Is the KRMD COO’s ownership direct or indirect after the reported trade?

The KRMD COO’s ownership is reported as direct after the trade. The Form 4 indicates 305,131 Common Stock shares held with ownership type coded as direct, reflecting his position after buying 5,000 shares at $3.88 per share.